Invesco
CTKB icon

Invesco’s Cytek Biosciences CTKB Stock Holding History

Invesco’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$823K Sell
185,671
-202,562
-52% -$865K ﹤0.01% 3023
2026
Q1 		$1.7M Sell
388,233
-10,564
-3% -$49.9K ﹤0.01% 2611
2025
Q4 		$2.01M Buy
398,797
+9,671
+2% +$44.9K ﹤0.01% 2605
2025
Q3 		$1.35M Buy
389,126
+45,467
+13% +$171K ﹤0.01% 2788
2025
Q2 		$1.17M Buy
343,659
+6,706
+2% +$22.3K ﹤0.01% 2782
2025
Q1 		$1.35M Buy
336,953
+9,893
+3% +$51.3K ﹤0.01% 2708
2024
Q4 		$2.12M Sell
327,060
-5,845
-2% -$34.8K ﹤0.01% 2595
2024
Q3 		$1.84M Buy
332,905
+12,434
+4% +$70.5K ﹤0.01% 2641
2024
Q2 		$1.79M Sell
320,471
-31,373
-9% -$188K ﹤0.01% 2628
2024
Q1 		$2.36M Buy
351,844
+26,235
+8% +$208K ﹤0.01% 2578
2023
Q4 		$2.97M Sell
325,609
-66,082
-17% -$416K ﹤0.01% 2472
2023
Q3 		$2.16M Buy
391,691
+19,145
+5% +$154K ﹤0.01% 2567
2023
Q2 		$3.18M Buy
372,546
+250,243
+205% +$2.24M ﹤0.01% 2460
2023
Q1 		$1.12M Buy
122,303
+73,992
+153% +$796K ﹤0.01% 2856
2022
Q4 		$493K Sell
48,311
-4,766
-9% -$64.1K ﹤0.01% 3273
2022
Q3 		$781K Buy
53,077
+416
+0.8% +$5.4K ﹤0.01% 3021
2022
Q2 		$565K Buy
52,661
+12,561
+31% +$125K ﹤0.01% 3271
2022
Q1 		$432K Buy
+40,100
New +$542K ﹤0.01% 3469

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Invesco's CTKB Position: Q2 2026 in Review

Invesco reduced its Cytek Biosciences (CTKB) stake by 52% in Q2 2026, selling an estimated $865K and leaving 185,671 shares worth $823K. The position accounts for ﹤0.01% of the portfolio, ranked #3023.

Invesco first reported a position in CTKB in Q1 2022 and has held it in 18 quarters since. The position peaked at $3.18M in Q2 2023. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Invesco held 185,671 shares of Cytek Biosciences worth $823K as of Q2 2026.
  • Invesco sold 202,562 Cytek Biosciences shares in Q2 2026, an estimated $865K.
  • Cytek Biosciences made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3023 holding.
  • Invesco first reported a position in Cytek Biosciences in Q1 2022 and has held it in 18 quarters since.
  • Invesco's Cytek Biosciences position peaked at $3.18M in Q2 2023.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.